MAIA Biotechnology Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
MAIA$1.09+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
MAIA Biote chnology, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
for the Year ended December 31, 2023
| Preferred Stock · Common Stock | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity | |
| Balance at December 31, 2022 | — | $— | 10,955,904 | $1,096 | $52,729,942 | $(44,207,272) | $(15,973) | $8,507,793 |
| Issuance of common shares upon exercise of stock options | — | — | 750 | 1 | 1,432 | — | — | 1,433 |
| Issuance of restricted stock | — | — | 291,469 | 28 | 731,633 | — | — | 731,661 |
| Stock-based compensation expense | — | — | — | — | 3,089,304 | — | — | 3,089,304 |
| Issuance of common shares in connection with At-The-Market financing, net of $428,396 of issuance costs | — | — | 758,388 | 76 | 1,154,361 | — | — | 1,154,437 |
| Issuance of common shares in connection with follow-on offering, net of $1,593,016 of issuance costs | — | — | 2,555,500 | 256 | 4,156,603 | — | — | 4,156,859 |
| Issuance of warrants to underwriter in connection with follow-on offering | — | — | — | — | 241,109 | — | — | 241,109 |
| Issuance of stock options to satisfy accrued bonus | — | — | — | — | 974,224 | — | — | 974,224 |
| Issuance of common shares in connection with direct offering, net of $702,202 of issuance costs | — | — | 2,424,243 | 242 | 1,393,641 | — | — | 1,393,883 |
| Foreign currency translation adjustment | — | — | — | — | — | — | (287) | (287) |
| Net loss | — | — | — | — | — | (19,772,905) | — | (19,772,905) |
| Balance at December 31, 2023 | — | $— | 16,986,254 | $1,699 | $64,472,249 | $(63,980,177) | $(16,260) | $477,511 |
MAIA Biotechnology, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
for the Year ended December 31, 2022
| Preferred Stock · Common Stock | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity | |
| Balance at December 31, 2021 | — | $— | 7,584,980 | $758 | $37,618,438 | $(28,437,993) | $— | $9,181,203 |
| Issuance of common shares upon exercise of stock options | — | — | 46,500 | 5 | 83,995 | — | — | 84,000 |
| Issuance of common shares upon exercise of warrants | — | — | 529,712 | 53 | 385,347 | — | — | 385,400 |
| Stock-based compensation | — | — | — | — | 2,319,427 | — | — | 2,319,427 |
| Issuance of common shares in connection with equity financing | — | — | 274,840 | 28 | 2,473,532 | — | — | 2,473,560 |
| Issuance of common shares in connection with initial public offering, net of $2,749,905 issuance cost | — | — | 2,300,000 | 230 | 8,749,865 | — | — | 8,750,095 |
| Issuance of ratchet shares | — | — | 219,872 | 22 | 1,099,338 | — | — | 1,099,360 |
| Modification of warrant in equity | — | — | — | — | 450,578 | — | — | 450,578 |
| Deemed dividend on modification of warrant | — | — | — | — | (450,578) | — | — | (450,578) |
| Foreign currency translation adjustment | — | — | — | — | — | — | (15,973) | (15,973) |
| Net loss | — | — | — | — | — | (15,769,279) | — | (15,769,279) |
| Balance at December 31, 2022 | — | $— | 10,955,904 | $1,096 | $52,729,942 | $(44,207,272) | (15,973) | $8,507,793 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.